Prohibiting certain insurers, nonprofit health service plans, and health maintenance organizations from imposing a step therapy or fail-first protocol for certain prescription drugs prescribed by a treating physician to treat a symptom of or side effect from the treatment of stage four metastatic cancer and use of the prescription drug is consistent with best practices for treatment of the condition.